Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease. 1984

E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002262 Carboxy-Lyases Enzymes that catalyze the addition of a carboxyl group to a compound (carboxylases) or the removal of a carboxyl group from a compound (decarboxylases). EC 4.1.1. Carboxy-Lyase,Decarboxylase,Decarboxylases,Carboxy Lyase,Carboxy Lyases
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001549 Benzamides BENZOIC ACID amides.
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250
D013976 Tiapamil Hydrochloride A phenylethylamine derivative that acts as a calcium antagonist showing hemodynamic effects in patients with acute myocardial infarction. Dimeditiapramine,Dimeditiapramine Hydrochloride,N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)-N-methyl-m-dithian-2-propylamin-1,1,3,3-tetroxide hydrochloride,Ro 11-1781,Tiapamil,Hydrochloride, Dimeditiapramine,Hydrochloride, Tiapamil,Ro 11 1781,Ro 111781

Related Publications

E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
January 1978, Journal of neural transmission,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
January 1980, The Mount Sinai journal of medicine, New York,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
January 1990, Movement disorders : official journal of the Movement Disorder Society,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
July 1987, La Clinica terapeutica,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
June 1985, Acta neurologica Scandinavica,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
May 2012, Parkinsonism & related disorders,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
September 1987, Acta neurologica Scandinavica,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
March 2010, Movement disorders : official journal of the Movement Disorder Society,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
January 2013, Journal of the American Geriatrics Society,
E Csanda, and M Tárczy, and A Takáts, and I Mogyorós, and A Köves, and K Bihari
October 1982, Annals of neurology,
Copied contents to your clipboard!